Barclays analyst Gena Wang lowered the firm’s price target on 4D Molecular (FDMT) to $33 from $38 and keeps an Overweight rating on the shares. The firm views the company’s Q3 update as “largely incremental.” The Otsuka deal and equity offering extend 4D’s cash runway to the second half of 2028, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FDMT:
- 4D Molecular Therapeutics Reports Strategic Gains in Q3 2025
- 4D Molecular sees cash runway into 2H28
- 4D Molecular reports Q3 EPS ($1.01), consensus (98c)
- 4D Molecular Therapeutics Closes $93.3 Million Stock Offering
- Bullish Outlook on 4D Molecular Therapeutics’ 4D-150: Promising Long-term Efficacy, Safety, and Financial Strength Justify Buy Rating